Indivior (NASDAQ:INDV) Sees Strong Trading Volume - Time to Buy?

On Friday, shares of Indivior PLC (NASDAQ:INDV) experienced a significant increase in trading volume. During mid-day trading, approximately 419,314 shares changed hands, marking a 6% rise from the previous day's volume of 396,994 shares. The stock was last traded at $7.58, having closed at $7.98 the day before.

Wall Street Analysts Forecast Growth

Indivior has attracted attention from multiple research analysts recently. Craig Hallum adjusted their price target for Indivior, reducing it from $20.00 to $16.00 while maintaining a "buy" rating. Similarly, Piper Sandler reaffirmed an "overweight" rating and set a new target price of $15.00, down from an earlier estimate of $22.00.

Indivior Stock Performance

The company's financial metrics reveal insights into its performance. Indivior has a debt-to-equity ratio of 23.50, a quick ratio of 0.68, and a current ratio of 0.85. With a market capitalization of $1.02 billion, the stock’s P/E ratio stands at 759.00 with a beta of 0.68. Over recent months, the company's 50-day moving average has been $11.11, while the 200-day moving average is $14.80.

Indivior last shared its quarterly earnings on July 25th, reporting earnings per share (EPS) of $0.44, which exceeded the consensus estimate of $0.40 by $0.04. The firm recorded a revenue of $299 million for the quarter, surpassing the analysts' expectation of $285.90 million. Analysts predict that Indivior PLC will achieve 1.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Recent activity among institutional investors and hedge funds indicates changing positions in Indivior. Notably, M&G Plc established a new position in the company, investing approximately $2,518,000 during the first quarter. Janus Henderson Group PLC increased its stake by 14.2% in the same quarter, bringing its total ownership to 440,121 shares valued at $9,424,000 after acquiring an additional 54,750 shares. Vanguard Group Inc. raised its holdings by 0.9% in the fourth quarter, owning 5,899,190 shares now worth $90,081,000 after adding 52,836 shares. Quadrature Capital Ltd also bought a new position in Indivior during the first quarter for about $1,523,000, while Susquehanna International Group Ltd acquired a new stake valued at $3,224,000 in the second quarter. Overall, institutional and hedge fund investors own 60.33% of Indivior's stock.

About Indivior

Indivior PLC, along with its subsidiaries, is involved in the development, manufacturing, and sales of buprenorphine-based prescription medications aimed at treating opioid dependence and associated disorders in the United States, the United Kingdom, and globally. The firm focuses on therapies for substance use disorders, severe mental illnesses, and opioid overdose cases.

Should you invest $1,000 in Indivior right now?

Before making any investment decisions regarding Indivior, consider that although it currently holds a "Buy" rating among analysts, the focus may be on other stocks that analysts believe offer better investment opportunities. MarketBeat, which tracks the insights of top-rated research analysts, has identified five stocks that are being recommended as better buys ahead of the wider market's notice.

Investors are encouraged to explore these recommendations further to make informed decisions about their investment portfolios.

Indivior, Trading, Stocks